Literature DB >> 16773213

Lipid peroxidation and activity of some antioxidant enzymes in patients with glioblastoma and astrocytoma.

Bartosz Woźniak1, Alina Woźniak, Heliodor A Kasprzak, Gerard Drewa, Celestyna Mila-Kierzenkowska, Tomasz Drewa, Grzegorz Planutis.   

Abstract

The aim of this study was to evaluate the concentration of malondialdehyde-MDA (one of the lipid peroxidation products)-in blood plasma and erythrocytes and the activity of superoxide dismutase (SOD) and catalase (CAT) in red blood cells of patients with a primary brain tumour. The study was performed on 24 patients with a brain tumour (9 with glioblastoma and 15 with asrocytoma) treated in the Department and Clinic of Neurosurgery and Neurotraumatology at Ludwik Rydygier Medical University in Bydgoszcz. The control group consisted of 20 healthy volunteers. A statistically significant higher MDA concentration in erythrocytes and blood plasma and a higher activity of SOD or CAT in erythrocytes was shown in patients with a brain tumour as compared to the control group. Neither the histological type of tumour nor surgery has an effect on the tested biochemical parameters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773213     DOI: 10.1007/s11060-006-9202-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  21 in total

1.  [Formation of superoxide radicals by the nuclear membranes of human brain tumors].

Authors:  A M Tarakhovskiĭ; V A Shliakhovenko; E N Zhmareva; I A Brodskaia; A V Peskin
Journal:  Biull Eksp Biol Med       Date:  1985-01

2.  Cell death and oxidative stress in gliomas.

Authors:  D S Tews
Journal:  Neuropathol Appl Neurobiol       Date:  1999-08       Impact factor: 8.090

3.  Control of vasogenic edema in a brain tumor model: comparison between dexamethasone and superoxide dismutase.

Authors:  Y Shoshan; T Siegal
Journal:  Neurosurgery       Date:  1996-12       Impact factor: 4.654

4.  Lazaroids inhibit proliferation of cultured human astrocytoma cells.

Authors:  P Arora; Y S Lee; T C Origitano; R D Wurster
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

5.  Study of the antioxidant enzymes in human brain tumors.

Authors:  P Y Pu; J Lan; S B Shan; E Q Huang; Y Bai; Y Guo; D H Jiang
Journal:  J Neurooncol       Date:  1996-08       Impact factor: 4.130

6.  [Lipid peroxidation and antioxidative activity in the tumor tissue and blood of patients with neuro-oncological diseases].

Authors:  L I Levchenko; M L Demchuk
Journal:  Zh Vopr Neirokhir Im N N Burdenko       Date:  1991 Jul-Aug

Review 7.  The osmotic/calcium stress theory of brain damage: are free radicals involved?

Authors:  T L Pazdernik; M Layton; S R Nelson; F E Samson
Journal:  Neurochem Res       Date:  1992-01       Impact factor: 3.996

8.  Xanthine oxidase levels in human brain tumors.

Authors:  E Kökoglu; A Belce; E Ozyurt; Z Tepeler
Journal:  Cancer Lett       Date:  1990-04-30       Impact factor: 8.679

9.  Superoxide radical inhibits catalase.

Authors:  Y Kono; I Fridovich
Journal:  J Biol Chem       Date:  1982-05-25       Impact factor: 5.157

10.  Levels of water-soluble antioxidants in astrocytoma and in adjacent tumor-free tissue.

Authors:  H Landolt; H Langemann; A Probst; O Gratzl
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more
  3 in total

1.  Malondialdehyde value as radical oxidative marker and endogenous antioxidant value analysis in brain tumor.

Authors:  Ridha Dharmajaya; Dina Keumala Sari
Journal:  Ann Med Surg (Lond)       Date:  2022-03-23

2.  Comparative analysis of antioxidative systems in malignant and benign brain tumours.

Authors:  Vojislav Bogosavljević; Milica Bajčetić; Ivan Spasojević
Journal:  Redox Rep       Date:  2014-09-23       Impact factor: 4.412

3.  Parameters of antioxidant barrier in different histopathologic types of pediatric cancers.

Authors:  Teresa Stachowicz-Stencel; Anna Synakiewicz; Anna Owczarzak; Aleksandra Sliwinska; Wieslawa Lysiak-Szydlowska; Anna Balcerska
Journal:  Contemp Oncol (Pozn)       Date:  2012-05-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.